Skip to content

What is CEDS and the endocannabinoid system

The endocannabinoid system is a messaging system in your body (a series of chemical transmitters and receptors) that modulate just about every physiological function in your body. The endocannabinoid system:

  • regulates pain and inflammation pathways – in your joints and organs
  • affects how you sleep and how you feel (emotions)
  • regulates your appetite and metabolism
  • affects your memory and thinking (cognition)
  • regulates gastro-intestinal / gut function
  • regulates the protection and development of nerves in your body

For different reasons, such as lifestyle triggers or genetic factors, the ECS can be under-functioning in many people, and this results in symptoms that often take years to develop. This is now known as Clinical Endocannabinoid Deficiency Syndrome (CEDS). Symptoms of CEDS may include

Anxiety and Depression

Migraines and Headaches

Gastro-intestinal and metabolism dysfunction

Nerve vulnerability and deterioration

Pain, Inflammation and Fibromyalgia

Memory, thinking and cognition problems

Insomnia and other Sleep issues

Repetitive failed treatment

If this is you, you may be one of the 3 million Australians with CEDS, book your free consultation to speak with our CEDS specialists.

The Studies Behind It

We have teamed up with CANNect Group and Monash Clinical Research to see how patients went with our treatments.
Our patient outcome results are in!

66% of patients reduced their opioid use while significantly improving their quality of life. 

Why not treat my symptoms, instead of the ECS

Many people will undergo many failed, or underperforming treatments of CEDS symptoms. CEDS is a widespread imbalance in the body, potentially resulting in a plethora of symptoms, and impacting the effectiveness of other treatments.

Ongoing Thanks

To a Pioneer and a Friend

We extend our sincerest thanks to Raphael Mechoulam, who needs no introduction as one of the world’s most accomplished research scientists in the area of cannabinoids and endocannabinoids. His research from 1963 enabled the first synthesis of THC as well as the research discovery of the endocannabinoids anandamide and 2-AG. Raphael continues to inspire our key research team around the world. Learn more about Raphael here.

Raphael Mechoulam a friend of eCS Clinic
Ken Clement, Director of eCS Clinic, seated with Raphael Mechoulam

The term CEDS is a relatively recent one. And that’s because there are so many things about the ECS that we are still discovering.